Danish pharmaceutical company Lundbeck reported revenue in line with expectations for the fourth quarter, while adjusted earnings surpassed forecasts. The board has proposed an increase in the regular dividend.
Revenue rose by 10.0 percent to DKK 6,093 million (5,541). This result compares with the company's analyst consensus, which stood at 6,113.
EBITDA came in at DKK 933 million (651), with an EBITDA margin of 15.3 percent (11.7).
Adjusted EBITDA amounted to DKK 1,609 million (1,151), ahead of the expected 1,540, with an adjusted EBITDA margin of 26.4 percent (20.8).
Profit before tax was DKK 460 million (680).
Net profit after tax reached DKK 51 million (590).
Earnings per share amounted to DKK 0.05 (0.60). Adjusted earnings per share were DKK 0.94 (1.06), which is 19.7 percent below the analyst consensus of 1.17.
The proposed regular dividend is DKK 1.15 per share (0.95).
“Lundbeck delivered strong progress in 2025, supported by consistent execution throughout the year and a solid fourth quarter. Record revenue reflects sustained momentum in our key growth drivers and disciplined implementation of our Focused Innovator Strategy. At the same time, our pipeline has made significant advances across several programs, and with multiple key milestones ahead in 2026, we expect that five to six mid- to late-stage assets will have advanced by year-end,” said CEO Charl van Zyl in a statement.
He continued:
“Two years into the Focused Innovator Strategy, disciplined capital reallocation and targeted investments are delivering tangible results, supporting continued growth in 2026 and long-term value creation.”
H Lundbeck A/S is a Denmark-based company active in the pharmaceuticals industry. It is engaged in the research, development, manufacture and marketing of pharmaceuticals for the treatment of brain disorders, such as Alzheimer’s disease, Bipolar disorder, depression, epilepsy, Huntington’s disease, Parkinson’s disease and schizophrenia. Its product portfolio includes: Cipralex for the treatment of depression and anxiety disorders, Ebixa for the treatment of Alzheimer’s disease, Azilect for the treatment of Parkinson’s disease, Xenazine for the treatment of Huntington’s disease and Sabril for the treatment of epilepsy, among others. The Company operates through a number of subsidiaries, such as Lundbeck SAS, Lundbeck GmbH, SIA Lundbeck Latvia and Lundbeck LLC.
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
ESG MSCI
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
